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identify conventional bacteria or viruses. Thirdly, more cases
of mild-to-moderate pneumonia were studied as
convalescent serum was an entry requirement; this resulted
in the exclusion of those who died from severe pneumonia.
Nevertheless, our conclusion that 'atypical' bacteria are a
major cause of community-acquired pneumonia in our area
remains valid. This has major implications for therapy.
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The usefulness of
cerebrospinal fluid tests for
neurosyphilis
H. G. Russouw, M. C. Roberts, R. A. Emsley,
J.J.Joubert
To determine the usefulness of cerebrospinal fluid (CSF)
tests for syphilis at a large academic hospital, clinical and
laboratory data on 644 patients in whom such testing was
requested over a 12-month period were analysed. In 198
cases (31 %) the Treponema paJlidum haemagglutination
(TPHA) screening test could not be performed bec~use of
insufficient fluid. Thirty-eight of the remaining pati.ents
were diagnosed as having active neurosyphilis.
Examination of 22 files of patients who had a positive
TPHA and fluorescent treponemal antibody absorption
(FTA-Abs) test together with a negative CSF Venereal
Disease Research Laboratory (VDRL) test revealed that
other CSF measures indicating disease activity (CSF
protein, cells or IgG index) were not utilised optimally.
In 10 (45%) of these patients neurosyphilis was not
diagnosed despite either abnormal or incomplete CSF
biochemical analysis, indicating that if the CSF VDRL is
used as the sole marker for disease activity, some cases
of neurosyphilis are likely to be missed.
S Afr Med J 1994; 84: 682-684.
Notwithstanding the fact that neurosyphilis remains an
important cause of psychiatric morbidity, particularly in
developing countries such as South Africa,' uncertainty still
exists about the application and interpretation of
cerebrospinal fluid (CSF) tests for syphilis!·' This applies
particularly to patients whose clinical picture is not clear cut
when the CSF Treponema pallidum haemagglutination
(fPHA) or fluorescent treponemal antibody absorption (FTA-
Abs) tests are positive in the presence of a negative CSF
Venereal Disease Research Laboratory (VDRL) test.
The CSF VDRL test is generally regarded as the best
available test for active neurosyphiliS, despite its low
sensitivity, which can result in some false negative results.
This sensitivity ranges between 10% and 89%, and is
lowest in asymptomatic neurosyphilis and tabes dorsalis.3
The TPHA and FTA-Abs tests are more sensitive and are
valuable as routine screening tests, but both remain positive
for an indefinite period after successful treatment: which
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:imits their usefulness in the diagnosis of recurring
'leurosyphilis activity. An elevated CSF cell count, protein
::ontent or IgG index are also indicative of activity, but are
',onspecific measurements and, furthermore, may be normal
1 patients with active neurosyphilis.'
In a study performed at Johns Hopkins Hospital in 1980,
)ans et al.' concluded that the CSF VORL test is used
,appropriately, without regard for clinical findings and results
f blood serology. This opinion was based on the finding that,
ut of 2 536 CSF VORL tests requested, only 3 (0,1 %) were
"active. However most of these CSF VORL tests were
Jquested without clear indications and without regard for
iood serology. The value of the CSF VORL test to exclude
symptomatic neurosyphilis has also been questioned
ecause of the limited advantage CSF analysis has over the
mpirical treatment of patients with asymptomatic late syphilis
.e. untreated syphilis of more than 1 year's duration).'" Also,
'3sts with a high rate of false- negative results cannot be used
lith confidence to exclude neurosyphilis.
The current study was undertaken to evaluate the
sefulness of CSF tests for neurosyphilis in a large
lcademic hospital. We were particularly interested in
.ssessing whether available markers were being optimally
Itilised and correctly interpreted - especially where there
vas doubt about disease activity.
ethod
lesults of all the tests for syphilis performed on the CSF of
ldult patients during the 12-month period from 1 July 1990
:) 30 June 1991 at Tygerberg Hospital were analysed
etrospectively. Tests for syphilis were requested for 644
Idults' CSF specimens during this period.
At the time of the study, the following laboratory protocol
for CSF analysis was followed. The TPHA and FTA IgG and
IgM tests were performed on each specimen. The VDRL test
was performed only in the event of any of these tests being
positive.
We applied the following criteria, adapted from Burke and
Schaberg,s to diagnose neurosyphilis: (/) positive CSF VDRL
test; or (if) negative VORL test, but positive TPHA or FTA-Abs
test, together with a raised cell count (more than 5 cells/m!),
protein concentration (> 0,45 g/1) or IgG index (> 0,6).
The number of patients who met these criteria and in
whom treatment for neurosyphilis had been initiated was
also determined, and the follow-up management of those
who had not received any treatment was investigated. Also,
in the patients with a negative CSF VORL test together with
a positive TPHA or FTA-Abs test, a more detailed analysis
was performed.
Results
Of the 644 specimens tested, 379 (59%) had negative TPHA
and FTA IgG and IgM tests, and no further analyses were
performed. In 198 patients (31 %), there was insufficient fluid
present for the TPHA test; this resulted in possible missed
diagnoses. Forty-five (31 %) of these 198 specimens had a
positive FTA-Abs IgG test, but had to be excluded from the
study as the CSF VDRL test had not been performed.
The TPHA and FTA-Abs IgG tests were both positive in 64
cases (10%). In 4 of these, there was insufficient fluid for the
VORL test. Of the remaining 60 specimens, 31 (52%) had
positive VDRL tests, and 29 (48%) negative VORL tests. Thus
out of a total of 442 CSF specimens with sufficient fluid for a
complete analysis, 7% had a positive CSF VORL titre.
'able I. Relevant data of 22 patients with positive TPHA and FTA-Abs tests', but negative VDRl titre in CSF
Serum IgG CSF CSF cells
-\ge (yrs) Presenting symptoms Clinical diagnosis VDRL titre index protein (gll) (/mm3)
'2 Delirium Multi-infarct dementia Neg NO N 1
i3 Delirium; hallucinations Delirium tremens NO NO NO NO
'4 Memory impairment Post-traumatic amnestic disorder Neg 0,55 0,29 0
·6 Progressive Neurosyphilfs 1:64 5,55 2,20 15
weakness in legs
~3 Delirium Neurosyphilis 1:20 NO 0,45 1
34 Seizures Epilepsy Neg 0,05 NO NO
16 Hallucinations Neurosyphilis 1:64 NO 1,30 0
'4 Hallucinations Schizophreniform disorder Neg 0,48 0,11 0
q Aggression Neurosyphilis 1:64 NO 0,35 1
;0 Fainting Diabetes mellitus Neg NO 0,42 2
.8 Delirium Epilepsy 1:80 0,48 0,16 0
'5 Headache Migraine Neg .0,58 0,25 0
;2 Weakness in legs Idiopathic proximal muscular atrophy 1:16 0,46 0,28 1
A Weakness in legs; ataxia Epilepsy; phenytoin toxicity Neg NO 1,00 3
2 Weakness in legs Cerebellar degeneration Neg NO 0,70 NO
·1 Monoparesis; Factitious disorder Neg 0,66 0,02 2
memory impairment
·6 Hallucinations Bipolar mood disorder 1:20 NO 0,15 1
0 Memory impairment Diabetes mellitus Neg NO 0,80 0
1 Headache; fever Meningococcal meningitis Neg 2,30 2,60 0
7 Headache; fainting Previously treated neurosyphilis 1:20 0,73 0,15 2
8 Personality change, Previously treated neurosyphilis 'Neg 0,77 0,82 2
cognitive decline
0 Delirium Previously treated neurosyphilis 1:40 2,02 0,14 0
o=not done; N =normal; Neg =negative,
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The 29 patients with a negative CSF VDRL but positive
TPHA or FTA-Abs test, were selected for further analysis.
We regarded this group as a potential source of missed
diagnoses, because of the high false-negative rate of the
VDRL test. Seven of the 29 files could not be traced.
Relevant clinical and laboratory data for the remaining 22
patients are given in Table I.
According to the diagnosis noted in the files by the
attending doctor, 7 of the 22 patients were diagnosed as
having active neurosyphilis on the basis of factors other than
a reactive CSF VDRL test (raised cells, protein content or
IgG index in 5, suggestive symptomatology in 2 in the
presence of a positive CSF TPHA and FTA-Abs test). These
patients were treated and followed up accordingly.
Assuming that the 31 patients with a reactive CSF VDRL test
were diagnosed and treated as having neurosyphilis, we
obtained a positive yield of 38 (5,9%) from the 644 patients
in whom tests for syphilis had been requested. However,
when we applied our criteria to the 22 cases with a negative
CSF VDRL but a positive TPHA or FTA-Abs test, 10 patients
met the criteria for neurosyphilis. In a further 7 cases the
diagnosis could not be excluded because a full biochemical
analysis was not requested, while only 5 had completely
normal CSF chemistry. Ten patients therefore were not
diagnosed as having neurosyphilis by the attending doctor,
despite either meeting our criteria for neurosyphilis on the
basis of abnormal biochemistry or the fact that the diagnosis
could not be ruled out because of incomplete biochemical
analyses. In only 1 patient could the abnormal CSF
chemistry be ascribed to other central nervous system
pathology. The remaining 9 patients had routine follow-up
arranged for them. However, at the time of discharge, no
reference was made to a consideration of the possibility of
neurosyphilis at follow-up.
Discussion
Given the grave consequences of a missed diagnosis, we
believe that a positive yield of 5,9% from all CSF specimens
tested for neurosyphilis confirms the usefulness of these
tests as a screening device in a population where the
disease is still relatively frequently encountered.
However, our findings also highlight a number of potential
pitfalls that may seriously jeopardise the usefulness of CSF
tests for neurosyphilis.
The fact that 6 of the 10 patients who met our study
criteria for neurosyphilis had a negative serum VDRL titre,
emphasises the limitations of this test as the sole indicator
for further investigation. It would seem prudent, therefore, to
perform a lumbar puncture should any of the serological
parameters for syphilis (TPHA, FTA-Abs and VDRL) be
abnormal in the blood of patients who present with
neurological or psychiatric symptoms.
The large number of specimens with insufficient fluid for a
complete analysis (31 %) was an unexpected finding. In our
laboratory a minimum of 1,5 ml fluid is necessary for the
microbiology and at least 2 ml for the chemistry in order to
perform the complete analysis, without which the value of
these tests is greatly diminished. Although it is sometimes
difficult to obtain sufficient fluid, this finding points'to a lack
of communication between the laboratory and clinicians.
This could be explained by the rapid turnover of staff in an
academic hospital.
It is generally accepted that a positive VDRL titre in the
CSF is indicative of disease activity. However, we found that
in the presence of a negative VDRL titre, neurosyphilis was
not considered, and that the other measurements in the CSF
were not adequately utilised, as revealed by the large number
of patients in whom an IgG index was not requested (50%).
Although the IgG index is not routinely requested in patients
with suspected neurosyphilis, we suggest that it be used in
such patients, in order to obtain a higher detection rate.
, It was also interesting to note the high proportion of
patients with positive TPHA and FTA-Abs tests but negative
VDRL tests who had biochemical abnormalities in the CSF
(45%). This again indicates that a negative VDRL test. does
not necessarily exclude neurosyphilis.
According to our criteria, there were 3 patients who had
false-negative CSF VDRL tests and 9 who were possible false-
negatives. Furthermore, the fact that 31 % of our cases could
not be analysed because of insufficient CSF samples indicates
that this is probably an underestimation. If such a large
percentage of cases is missed in a tertiary hospitcll, one can
surmise that even more are missed at lower levels of care.
Like Stingl et al.,'° we found that follow-up of p'atients wit[l
neurosyphilis was inconsistent, particularly for those initially
suspected to have neurosyphilis but who were subsequently
found to have a negative CSF VDRL test. Because of the
insensitivity of the VDRL test and the poor predictive value
of CSF cell and protein content or IgG index, we suggest
that all patients presenting with psychiatric or neurological
symptoms who have a positive TPHA or FTA-Abs test of the
CSF be .carefully followed up for signs of active infection,
including a repeat lumbar puncture after 1 - 2 months. The
lack of infallible markers for the diagnosis of active
neurosyphilis underlines once again the need for further
research in this area.
To increase the awareness of the volume of CSF required
to perform these tests, we suggest that the minimum
volume be printed on the laboratories' request forms. We
also suggest that the IgG index be performed routinely in
the event of positive CSF TPHA and FTA-Abs tests. The
laboratory staff may also be required to suggest follow-up
testing on the laboratory report form. After the
implementation of these suggestions, follow-up studies are
indicated to determine their success in improving the utility
of CSF tests for neurosyphilis.
This work was supported by the Medical Research
Council of South Africa.
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